Voyager Therapeutics Inc (NASDAQ: VYGR) has a higher price-to-earnings ratio of 7.97x compared to its average ratio, The 36-month beta value for VYGR is at 0.88. Analysts have varying views on the stock, with 8 analysts rating it as a “buy,” 5 rating it as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for VYGR is 45.09M, and currently, shorts hold a 6.55% of that float. The average trading volume for VYGR on November 15, 2024 was 554.09K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
VYGR) stock’s latest price update
Voyager Therapeutics Inc (NASDAQ: VYGR) has seen a decline in its stock price by -7.61 in relation to its previous close of 6.22. However, the company has experienced a -19.40% decline in its stock price over the last five trading sessions. seekingalpha.com reported 2024-11-12 that Voyager Therapeutics, Inc. (NASDAQ:VYGR ) Q3 2024 Results Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Trista Morrison – Chief Corporate Affairs Officer and Chief of Staff to the CEO Alfred Sandrock – President and Chief Executive Officer Toby Ferguson – Chief Medical Officer Todd Carter – Chief Scientific Officer Nathan Jorgensen – Chief Financial Officer Conference Call Participants Phil Nadeau – TD Cowen Jack Allen – Robert W. Baird Joon Lee – Truist Securities Jay Olson – Oppenheimer & Co. Lili Nsongo – Leerink Partners Patrick Trucchio – HC Wainwright Operator Good afternoon, and welcome to the Voyager Therapeutics Third Quarter 2024 Financial Results Conference Call.
VYGR’s Market Performance
Voyager Therapeutics Inc (VYGR) has experienced a -19.40% fall in stock performance for the past week, with a -28.25% drop in the past month, and a -13.71% drop in the past quarter. The volatility ratio for the week is 7.10%, and the volatility levels for the past 30 days are at 6.65% for VYGR. The simple moving average for the past 20 days is -15.28% for VYGR’s stock, with a -26.45% simple moving average for the past 200 days.
Analysts’ Opinion of VYGR
Many brokerage firms have already submitted their reports for VYGR stocks, with Leerink Partners repeating the rating for VYGR by listing it as a “Outperform.” The predicted price for VYGR in the upcoming period, according to Leerink Partners is $15 based on the research report published on October 16, 2024 of the current year 2024.
Guggenheim, on the other hand, stated in their research note that they expect to see VYGR reach a price target of $22. The rating they have provided for VYGR stocks is “Buy” according to the report published on March 26th, 2024.
H.C. Wainwright gave a rating of “Buy” to VYGR, setting the target price at $30 in the report published on March 19th of the current year.
VYGR Trading at -13.24% from the 50-Day Moving Average
After a stumble in the market that brought VYGR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -50.97% of loss for the given period.
Volatility was left at 6.65%, however, over the last 30 days, the volatility rate increased by 7.10%, as shares sank -28.15% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -5.42% lower at present.
During the last 5 trading sessions, VYGR fell by -18.68%, which changed the moving average for the period of 200-days by -23.31% in comparison to the 20-day moving average, which settled at $6.79. In addition, Voyager Therapeutics Inc saw -31.91% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VYGR starting from Fahey Sandell Jacquelyn, who sale 5,999 shares at the price of $5.82 back on Oct 02 ’24. After this action, Fahey Sandell Jacquelyn now owns 86,001 shares of Voyager Therapeutics Inc, valued at $34,914 using the latest closing price.
Fahey Sandell Jacquelyn, the Officer of Voyager Therapeutics Inc, proposed sale 5,999 shares at $5.82 during a trade that took place back on Oct 02 ’24, which means that Fahey Sandell Jacquelyn is holding shares at $34,920 based on the most recent closing price.
Stock Fundamentals for VYGR
Current profitability levels for the company are sitting at:
- 0.06 for the present operating margin
- 0.77 for the gross margin
The net margin for Voyager Therapeutics Inc stands at 0.16. The total capital return value is set at 0.02. Equity return is now at value 10.22, with 7.18 for asset returns.
Currently, EBITDA for the company is 126.45 million with net debt to EBITDA at -8.66. When we switch over and look at the enterprise to sales, we see a ratio of 1.24. The receivables turnover for the company is 10.27for trailing twelve months and the total asset turnover is 0.38. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.45.
Conclusion
In conclusion, Voyager Therapeutics Inc (VYGR) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
